Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mahalya Gogerly-Moragoda"'
Publikováno v:
BMC Public Health, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background The COVID-19 pandemic exacerbated preexisting barriers to accessing healthcare and social services faced by asylum seekers to the United States. This study aimed to uncover the impact of the first year of the COVID-19 pandemic on
Externí odkaz:
https://doaj.org/article/b2448f1318544e94a0b9fa3a097b5c84
Autor:
Qian Qin, Tomi Jun, Bo Wang, Vaibhav G. Patel, George Mellgard, Xiaobo Zhong, Mahalya Gogerly-Moragoda, Anish B. Parikh, Amanda Leiter, Emily J. Gallagher, Parissa Alerasool, Philip Garcia, Himanshu Joshi, MBBS, Matthew Galsky, William K. Oh, Che-Kai Tsao
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-11 (2022)
Abstract Objectives Response to immune checkpoint inhibitor (ICI) remains limited to a subset of patients and predictive biomarkers of response remains an unmet need, limiting our ability to provide precision medicine. Using real-world data, we aimed
Externí odkaz:
https://doaj.org/article/37da49ca41554ae38f0bb80d40f404bf
Autor:
George Mellgard, Vaibhav G. Patel, Xiaobo Zhong, Himanshu Joshi, Qian Qin, Bo Wang, Anish Parikh, Tomi Jun, Parissa Alerasool, Philip Garcia, Mahalya Gogerly-Moragoda, Amanda Leiter, Emily J Gallagher, William K. Oh, Matthew D. Galsky, Che-Kai Tsao
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Purpose: Stress-induced adrenergic signaling can suppress the immune system. In animal models, pharmacological beta-blockade stimulates CD8+ T-cell activity and improves clinical activity of immune checkpoint blockade (ICB) in inhibiting tumor growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e95e3affb488d534b7d29b7de1315145
https://doi.org/10.1007/s00432-022-04159-y
https://doi.org/10.1007/s00432-022-04159-y
Autor:
Matt D. Galsky, Siamak Daneshmand, Sara C Lewis, Kevin G. Chan, Tanya B. Dorff, Jeremy Paul Cetnar, Ronac Mamtani, Christos Kyriakopoulos, Mahalya Gogerly-Moragoda, Sudeh Izadmehr, Menggang Yu, Qianqian Zhao, Tomi Jun, Reza Mehrazin, John P. Sfakianos, Sumanta Monty Pal
Publikováno v:
Journal of Clinical Oncology. 41:447-447
447 Background: Transurethral resection of bladder tumor (TURBT) plus systemic therapy has been known for decades to achieve durable bladder-intact survival in a subset of patients with MIBC but efforts to advance this paradigm have been complicated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1c31bd216b798b23b9b865838659bcd
https://doi.org/10.1200/jco.2023.41.6_suppl.447
https://doi.org/10.1200/jco.2023.41.6_suppl.447
Autor:
Robin A. Ross, Heather Brouwer, Yuan Lui, Bryan A Ballif, Ralph C. Budd, Anisha Mahalya Gogerly-Moragoda, Ana Filipa L.O.M. Santos, Kuberan Balagurunathan, Sumana Sharma, Gavin J. Wright, Simon J. Davis, Cheryl Collins
Publikováno v:
The Journal of Immunology Author Choice
Key Points TCR-γδ tetramer identified ligand expression by flow cytometry. TCR-γδ ligands were induced on activated monocytes or T cells. Bioinformatics combined with mass spectrometry produced an overlapping list of 16 candidate ligands.
Vi
Vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b002cf3729ada76e5cf1502a2bb4ef1c
https://doi.org/10.4049/jimmunol.1900451
https://doi.org/10.4049/jimmunol.1900451
Autor:
Mishell Ganchala, Mahalya Gogerly-Moragoda, Catherine Swarts, James Fleming, Katherine Small, Helen Liu, Alicia Philippou, Caileigh McGoldrick, Claire Ufongene
Publikováno v:
American Journal of Gastroenterology. 116:S661-S661
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d413198ee1dfa758d91be860589d3417
https://doi.org/10.14309/01.ajg.0000779288.68163.0c
https://doi.org/10.14309/01.ajg.0000779288.68163.0c
Autor:
Mahalya Gogerly-Moragoda, Teja Ganta, William Oh, Amanda Leiter, Che-Kai Tsao, Matthew D. Galsky, Qian Qin, Vaibhav G. Patel, Emily J. Gallagher, Tomi Jun, Bo Wang, George Mellgard
Publikováno v:
Journal of Clinical Oncology. 38:e15109-e15109
e15109 Background: Regulatory T cells play a key role in protecting kidney cells from ischemic injury. Immune checkpoint inhibitors (ICIs) may increase the risk of acute kidney injury via inhibition of regulatory T cells [1, 2]. Prospective clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f612bdf2ca38e236814554fd5f1bdbe
https://doi.org/10.1200/jco.2020.38.15_suppl.e15109
https://doi.org/10.1200/jco.2020.38.15_suppl.e15109
Autor:
Mahalya Gogerly-Moragoda, Xiaobo Zhong, Che-Kai Tsao, Qian Qin, Matthew D. Galsky, Vaibhav G. Patel, Emily J. Gallagher, Amanda Leiter, George Mellgard, William Oh, Bo Wang, Justin Lin
Publikováno v:
Journal of Clinical Oncology. 38:e15157-e15157
e15157 Background: Immune checkpoint inhibitors (ICIs) are widely adopted for multiple indications across various malignancies. Despite the surge in their use, what occurs at radiographic progression (rPOD) remains poorly characterized. Herein, we de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1c0725a0ed902f6b8e312cf4a3e9e0a
https://doi.org/10.1200/jco.2020.38.15_suppl.e15157
https://doi.org/10.1200/jco.2020.38.15_suppl.e15157
Autor:
Amanda Leiter, Matthew D. Galsky, George Mellgard, Che-Kai Tsao, Tomi Jun, Qian Qin, Vaibhav G. Patel, Mahalya Gogerly-Moragoda, William Oh, Teja Ganta, Bo Wang, Emily J. Gallagher
Publikováno v:
Journal of Clinical Oncology. 38:e15097-e15097
e15097 Background: Improved immunotherapy (IO) outcomes have been observed among non-small cell lung cancer patients with a current or former smoking history. This is thought to be a consequence of increased immunogenic mutation burden among smoking-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b945d7d7a9c869bf5cf91fc16ecfbed8
https://doi.org/10.1200/jco.2020.38.15_suppl.e15097
https://doi.org/10.1200/jco.2020.38.15_suppl.e15097
Autor:
Matthew D. Galsky, Qian Qin, Vaibhav G. Patel, Bo Wang, William Oh, Amanda Leiter, George Mellgard, Che-Kai Tsao, Emily J. Gallagher, Mahalya Gogerly-Moragoda, Xiaobo Zhong, Anish B. Parikh
Publikováno v:
Journal of Clinical Oncology. 38:e15160-e15160
e15160 Background: Development (DV) of immune-related adverse events (IRAEs) to immune checkpoint inhibitor (ICI) have been associated (asso/) with (w/) favorable treatment (tx) response, but heterogeneity in clinical presentation remains a concern.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d2b6a486b6f64189e7e1b16f9964a8b
https://doi.org/10.1200/jco.2020.38.15_suppl.e15160
https://doi.org/10.1200/jco.2020.38.15_suppl.e15160